Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks

Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks

Abstract Introduction Patients with ankylosing spondylitis (AS) are burdened with symptoms impacting work productivity measured by presenteeism, absenteeism, overall work impairment, and activity impairment. Ixekizumab, a high-affinity monoclonal antibody selectively targeting interleukin-17A, has b...

Full description

Bibliographic Details
Main Authors: Helena Marzo-Ortega, Philip J. Mease, Proton Rahman, Victoria Navarro-Compán, Vibeke Strand, Maxime Dougados, Bernard Combe, James Cheng-Chung Wei, Xenofon Baraliakos, Theresa Hunter, David Sandoval, Xiaoqi Li, Baojin Zhu, Louis Bessette, Atul Deodhar
Format: Article
Language:English
Published: Adis, Springer Healthcare 2020-08-01
Series:Rheumatology and Therapy
Subjects:
Ankylosing spondylitis
Axial spondyloarthritis
Ixekizumab
Radiographic axial spondyloarthritis
Work productivity
Online Access:https://doi.org/10.1007/s40744-020-00225-4

Internet

https://doi.org/10.1007/s40744-020-00225-4

Similar Items